Lyra Therapeutics (LYRA) Amortizatization of Intangibles (2023 - 2024)
Quarterly Amortizatization of Intangibles fell 75.46% to $267000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $2.3 million through Dec 2024, down 34.9% year-over-year, with the annual reading at $2.3 million for FY2024, 34.9% down from the prior year.
Lyra Therapeutics' Amortizatization of Intangibles history spans 2 years, with the latest figure at $267000.0 for Q4 2024.
- Amortizatization of Intangibles came in at $267000.0 for Q4 2024, down from $401000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $1.1 million in Q4 2023 to a low of $267000.0 in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 13,267.00 |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | - |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | - |
| 10 | Lyra Therapeutics | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 267,000.00 |
| Dec 31, 2024 | 267,000.00 |
| Sep 30, 2024 | 401,000.00 |
| Sep 30, 2024 | 401,000.00 |
| Jun 30, 2024 | 675,000.00 |
| Jun 30, 2024 | 675,000.00 |
| Mar 31, 2024 | 933,000.00 |
| Mar 31, 2024 | 933,000.00 |
| Dec 31, 2023 | 1.09 Mn |
| Dec 31, 2023 | 1.09 Mn |
| Sep 30, 2023 | 1.06 Mn |
| Sep 30, 2023 | 1.06 Mn |
| Jun 30, 2023 | 626,000.00 |
| Jun 30, 2023 | 626,000.00 |
| Mar 31, 2023 | 726,000.00 |
| Mar 31, 2023 | 726,000.00 |